GLP-1 diabetes and weight-loss drug facing NAION risk warnings as FDA pushes new labels; Novo Nordisk’s Ozempic remains a leading, contested treatment in a fast-changing field.
The FDA has required warning labels on GLP-1 drugs used for obesity and diabetes after reviewing data that link a rare eye condition, NAION, to these medications. The warning covers a dozen drugs, including Ozempic, Wegovy, Mounjaro and Zepbound. Trials and real-world data show NAION occurrences are rare but higher than in non-GLP-1 therapies.
A BBC Business report notes rising use of weight-loss drugs in 2024-25, with a focus on male users and safety concerns, while other outlets explore personal journeys with GLP-1 medications and gut health trends.
New study finds Med-South, a North Carolina adaptation of the Mediterranean diet, helps weight loss and improves diet quality compared with Weight Watchers. Both programs achieve similar weight loss, but Med-South yields higher-quality eating habits through phased support over two years.
A study from Anglia Ruskin University finds traditional dieting is less effective for men, who view dieting as restrictive and feminine. Partners often support men, while male-focused programmes that emphasize quick wins, social competition and strength may boost engagement. Researchers advocate practical, non-dieting strategies and sport-related challenges.
GLP-1 medications are being increasingly prescribed off-label to children aged 8–11 in the US, despite no FDA approval for under-12s. A NYU Langone study shows a dramatic rise in June 2026, while experts warn about long-term effects and the broader obesity crisis.
A set of weight-loss drugs known as GLP-1s show strong average effectiveness, but a notable minority of patients experience little to no weight loss. Researchers are investigating why responses vary, aiming to tailor treatments and improve cost-effectiveness.
Investors have pushed new biotech winners — from Novo Nordisk’s semaglutide pill to startups tackling baldness and targeted autoimmune drugs — while market enthusiasm has cooled for some forecasts. Novo Nordisk has released a daily weight‑loss pill used by over 1.5 million people; hair‑loss startups have sent small caps soaring; India’s low‑cost GLP‑1 generics have underperformed expectations.
Star Trek’s 60th anniversary is marred by debate over inclusivity and the franchise’s future. Multiple outlets report on cancellation of a Paramount+ series, with actors defending the franchise’s progressive values while critics question its current direction. Readers are watching closely as sponsors and fans weigh the franchise’s next moves.
Companies are reviewing coverage for GLP-1 weight-loss drugs as costs rise. Some have already trimmed benefits, while others cite long-term employee health benefits as a reason to maintain or adjust coverage. The trend could raise healthcare costs for employers and influence benefits strategies.
Novo has laid out a plan to diversify beyond Wegovy and Ozempic as it faces looming exclusivity losses. Capital Markets Day signals a push into cardiovascular, liver and blood disorders with a target to expand its pipeline, while investors question credibility and near-term milestones amid a evolving GLP-1 landscape dominated by Lilly.
Lawsuits allege GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), an eye condition that can cause permanent vision loss. Novo Nordisk and Eli Lilly dispute the claims as regulators review data; meanwhile trials and studies show mixed signals about risk.
Walmart has expanded benefits for associates, adding 12 weeks of neonatal ICU leave and enabling second opinions for rare conditions. It also joins Novo and Lilly drug coverage for Type 2 diabetics at no cost, while premium increases are minimized. The moves come ahead of open enrollment and build on years of compensation improvements.
The FDA has required safety labeling for GLP-1 receptor agonists, warning of a potential link to non-arteritic anterior ischemic optic neuropathy (NAION). While NAION is rare, the agency says cases have been reported and risk factors overlap with patients using GLP-1 therapies. Health providers are urged to monitor for painless vision loss and refer promptly to ophthalmology if suspected.